Trending...
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
CHICAGO - illiNews -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the beauty and life science industries today announced their partnership to offer our customers additional value-add services.
"We are absolutely thrilled about the incredible opportunities that this partnership brings to the table!" comments Patrick Windsor, Managing Director of Risetime. "By harnessing Risetime's exceptional expertise in FDA regulation and seamlessly integrating it with the cutting-edge CARA Platform, we're setting the stage for an extraordinary level of support to the Cosmetic and Beauty industries, ensuring their complete compliance with MoCRA regulations like never before!"
The key focus of this partnership will be the configuration of the CARA Platform for the Cosmetic and Beauty industries and support of the current MoCRA FDA regulations. As a data and content management platform, CARA helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes and remain compliant. The unified CARA Life Sciences Platform™ is the pre-configured, out-of-the-box layer with standardised apps for Regulatory, Quality, Safety, and Clinical processes, powered by a single structured data lake that gives users instant access to cross-functional data and enables powerful process optimisation for pharmaceutical companies. This partnership will allow Generis to further expand and fine-tune their offering for the Cosmetics industry.
More on illi News
"Our partnership with Risetime is a very exciting opportunity." commented James Kelleher, CEO of Generis. "Our CARA Platform provides rich functionality for companies across all regulated industries to remain compliant and keep up with the changing regulations, and with the expertise and guidance provided by the Risetime we can ensure that customers are thriving and improving the way their organisation works."
About Risetime
Risetime is a Chicago-based service provider that offers exceptional services to clients across diverse industries with our skilled personnel and robust infrastructure.
Our Digital Content Managers use their elevated understanding of healthcare and pharmaceutical industry requirements, to handle assets and metadata correctly in an FDA regulated industry.
More at risetime.com
About Generis
Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com.
More on illi News
"We are absolutely thrilled about the incredible opportunities that this partnership brings to the table!" comments Patrick Windsor, Managing Director of Risetime. "By harnessing Risetime's exceptional expertise in FDA regulation and seamlessly integrating it with the cutting-edge CARA Platform, we're setting the stage for an extraordinary level of support to the Cosmetic and Beauty industries, ensuring their complete compliance with MoCRA regulations like never before!"
The key focus of this partnership will be the configuration of the CARA Platform for the Cosmetic and Beauty industries and support of the current MoCRA FDA regulations. As a data and content management platform, CARA helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes and remain compliant. The unified CARA Life Sciences Platform™ is the pre-configured, out-of-the-box layer with standardised apps for Regulatory, Quality, Safety, and Clinical processes, powered by a single structured data lake that gives users instant access to cross-functional data and enables powerful process optimisation for pharmaceutical companies. This partnership will allow Generis to further expand and fine-tune their offering for the Cosmetics industry.
More on illi News
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Illinois 45th District Candidate Josh Atkinson Introduces a New Way to Reach Voters
"Our partnership with Risetime is a very exciting opportunity." commented James Kelleher, CEO of Generis. "Our CARA Platform provides rich functionality for companies across all regulated industries to remain compliant and keep up with the changing regulations, and with the expertise and guidance provided by the Risetime we can ensure that customers are thriving and improving the way their organisation works."
About Risetime
Risetime is a Chicago-based service provider that offers exceptional services to clients across diverse industries with our skilled personnel and robust infrastructure.
Our Digital Content Managers use their elevated understanding of healthcare and pharmaceutical industry requirements, to handle assets and metadata correctly in an FDA regulated industry.
More at risetime.com
About Generis
Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com.
More on illi News
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Suburban Orthopaedics Expands Spine Team with Board-Certified Surgeon Joseph Brindise, DO
- Naperville: Drive Sober or Get Pulled Over This Season
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
Source: Generis
0 Comments
Latest on illi News
- EraMix Financial Union Launches Institutional Sentiment Index with Roland Haverford
- Chicago: City Council Approves ADU Expansion In Additional Single-family Districts, Bringing Total To 28 Wards With Construction Eligibility
- City Council Approves Land Sale To Support Chicago Torture Justice Memorial
- Various Measures Introduced To And Approved By The Chicago City Council
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
- Ace Watkins (Public Announcement)Elevates R&B with New Single "Higher" a Soulful Slow-burning Anthem
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
- Accelerating Precious Metals Expansion and Digital Asset Innovation Ahead of 2026: Asia Broadband Inc. (Stock Symbol: AABB)
- Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
- London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success
- myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
- Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
- ❄️ Winter Feature: Stay Comfortable at Cold-Weather Events
- Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
- Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
- Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
- Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
- Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
- Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban